Cardiology

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

A family medicine physician shares a case of massive PE presenting as syncope and explains the history questions that prevent missed DVT diagnoses in primary care.

Primary care physicians enhance early detection and management of vascular diseases, emphasizing patient history, screening, and strong relationships for better outcomes.

Highlights include size-based surveillance protocols, referral timing, cardiovascular risk reduction, and coordination with vascular surgery.

Managing post–MI distress is no longer optional—it’s essential to comprehensive cardiac recovery, according to a new AHA statement.

Emergency medicine physician Kabiul Haque, MD, discusses USPSTF screening guidelines for abdominal aortic aneurysm.

Kabiul Haque, MD, a family medicine physician, shares his four-pillar approach to preventing PAD progression.

Based on the PREVENT algorithm's estimates of 10-year ASCVD risk, 4.2 million adults may need to be reevaluated for aspirin discontinuation, authors reported.

AstraZeneca will share the positive topline 24-hour BP monitoring data with global regulatory authorities and present findings at the 2025 AHA Scientific Sessions.

Evolocumab significantly reduced major cardiovascular events in high-risk patients without prior heart attack or stroke, making it the first PCSK9 inhibitor with proven benefit in both primary and secondary prevention.

The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Your daily dose of the clinical news you may have missed.

The study found that although PREVENT-generated risk estimates were more consistent in a broad population, PCE estimates were more accurate in those taking statins.

Your daily dose of the clinical news you may have missed.

Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Analysis presented at AHA Hypertension 2025 showed fewer than 6% of US adults use salt substitutes, despite their potential to improve BP control.

A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.

Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.